{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:07:00Z","timestamp":1792667220613,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CZ.1.05\/1.1.00\/02.0109"],"award-info":[{"award-number":["CZ.1.05\/1.1.00\/02.0109"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["PRVOUK P24\/LF1\/3"],"award-info":[{"award-number":["PRVOUK P24\/LF1\/3"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["SVV 260 265\/2016"],"award-info":[{"award-number":["SVV 260 265\/2016"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["15-14200S"],"award-info":[{"award-number":["15-14200S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00023736"],"award-info":[{"award-number":["00023736"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["15-32961A"],"award-info":[{"award-number":["15-32961A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["ERDF OPPK CZ.2.16\/3.1.00\/24001"],"award-info":[{"award-number":["ERDF OPPK CZ.2.16\/3.1.00\/24001"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["ERDF OPPK CZ.2.16\/3.1.00\/28007"],"award-info":[{"award-number":["ERDF OPPK CZ.2.16\/3.1.00\/28007"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.phrs.2016.11.010","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T14:46:10Z","timestamp":1479393970000},"page":"242-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Therapeutic potential of hepcidin \u2212 the master regulator of iron metabolism"],"prefix":"10.1016","volume":"115","author":[{"given":"Daniel","family":"Vyoral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jiri Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.11.010_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbagen.2011.08.002","article-title":"The long history of iron in the Universe and in health and disease","volume":"1820","author":"Sheftel","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2016.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.bbamcr.2015.01.018","article-title":"Emerging critical roles of Fe-S clusters in DNA replication and repair","volume":"1853","author":"Fuss","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2016.11.010_bib0015","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.11.010_bib0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease","volume":"366","author":"Fleming","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.11.010_bib0030","doi-asserted-by":"crossref","first-page":"18975","DOI":"10.1074\/jbc.R115.650150","article-title":"Regulation of iron metabolism by hepcidin under conditions of inflammation","volume":"290","author":"Schmidt","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.semnephrol.2016.05.002","article-title":"Disorders of iron metabolism and anemia in chronic kidney disease","volume":"36","author":"Panwar","year":"2016","journal-title":"Semin. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2016.11.010_bib0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcmd.2007.07.009","article-title":"Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin","volume":"40","author":"Valore","year":"2008","journal-title":"Blood Cells. Mol. Dis."},{"issue":"May (6)","key":"10.1016\/j.phrs.2016.11.010_bib0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcmd.2009.03.008","article-title":"Activation and inactivation of the iron hormone hepcidin: biochemical characterization of prohepcidin cleavage and sequential degradation to N-terminally truncated hepcidin isoforms","volume":"43","author":"Schranz","year":"2009","journal-title":"Blood Cells. Mol. Dis."},{"key":"10.1016\/j.phrs.2016.11.010_bib0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.320","article-title":"Lack of the bone morphogenetic protein BMP6 induces massive iron overload","volume":"41","author":"Meynard","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2016.11.010_bib0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4172\/2155-9600.1000521","article-title":"Hepcidin regulation by bone morphogenetic protein signaling and iron homeostasis","volume":"6","author":"Rodova","year":"2016","journal-title":"J. Nutr. Food Sci."},{"key":"10.1016\/j.phrs.2016.11.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150014","article-title":"Hepcidin: regulation of the master iron regulator","volume":"35","author":"Rishi","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.phrs.2016.11.010_bib0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease","volume":"366","author":"Fleming","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.11.010_bib0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2013-06-427757","article-title":"The liver: conductor of systemic iron balance","volume":"123","author":"Meynard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ajh.23110","article-title":"Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation","volume":"87","author":"Sun","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.686.686","article-title":"Alk3, a BMP type receptor is required for the induction of hepatic hepcidin gene expression by interleukin-6","volume":"118","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0085","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"issue":"May Suppl (1)","key":"10.1016\/j.phrs.2016.11.010_bib0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12505","article-title":"The mutual control of iron and erythropoiesis","volume":"38","author":"Camaschella","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/intimm\/dxu144","article-title":"Analysis of IL-22 contribution to hepcidin induction and hypoferremia during the response to LPS in vivo","volume":"27","author":"Wallace","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1210\/en.2015-1747","article-title":"Activin B induces noncanonical SMAD1\/5\/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice","volume":"157","author":"Canali","year":"2016","journal-title":"Endocrinology"},{"issue":"May (15)","key":"10.1016\/j.phrs.2016.11.010_bib0105","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2012-11-427765","article-title":"The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions","volume":"122","author":"Mastrogiannaki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0110","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0115","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"Suppl (1)","key":"10.1016\/j.phrs.2016.11.010_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12505","article-title":"The mutual control of iron and erythropoiesis","author":"Camaschella","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0125","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1182\/blood-2009-01-201590","article-title":"Hepcidin the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood","volume":"113","author":"Peslova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0130","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1373\/clinchem.2012.186916","article-title":"Binding of hepcidin to plasma proteins","volume":"58","author":"Itkonen","year":"2012","journal-title":"Clin. Chem."},{"issue":"January (29)","key":"10.1016\/j.phrs.2016.11.010_bib0135","article-title":"Renal handling of circulating and renal-synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury","author":"van Swelm","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0140","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0145","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1373\/clinchem.2009.140053","article-title":"Hepcidin in human iron disorders: diagnostic implications","volume":"57","author":"Kroot","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3324\/haematol.11705","article-title":"Hepcidin: from discovery to differential diagnosis","volume":"93","author":"Kemna","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2016.11.010_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ab.2009.03.039","article-title":"(Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies","volume":"389","author":"Kroot","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1373\/clinchem.2012.194977","article-title":"Diurnal rhythm rather than dietary iron mediates daily hepcidin variations","volume":"59","author":"Schaap","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0165","doi-asserted-by":"crossref","first-page":"e75518","DOI":"10.1371\/journal.pone.0075518","article-title":"Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform","volume":"8","author":"Laarakkers","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.11.010_bib0170","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1373\/clinchem.2010.149187","article-title":"Immunochemical and mass-spectrometry based serum hepcidin assays for iron metabolism disorders","volume":"56","author":"Kroot","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0175","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2215\/CJN.05990809","article-title":"Current status of the measurement of blood hepcidin levels in chronic kidney disease","author":"Macdougall","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ajh.23289","article-title":"Second round robin for plasma hepcidin methods: first steps toward harmonization","volume":"87","author":"Kroot","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0185","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0190","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","article-title":"Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material","volume":"62","author":"van der Vorm","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0195","first-page":"1321","article-title":"Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies","volume":"35","author":"De Falco","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.phrs.2016.11.010_bib0200","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1182\/blood-2014-01-548776","article-title":"Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis","volume":"123","author":"Donker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0205","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1182\/blood-2008-12-195651","article-title":"Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications","volume":"113","author":"Theurl","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0210","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/art.30623","article-title":"Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia","volume":"63","author":"van Santen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2016.11.010_bib0215","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1373\/clinchem.2014.229179","article-title":"Hepcidin and the global burden of iron deficiency","volume":"61","author":"Ganz","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0220","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMcibr1304338","article-title":"Treating iron overload","volume":"368","author":"Camaschella","year":"2013","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.11.010_bib0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.tips.2014.01.004","article-title":"The pathophysiology and pharmacology of hepcidin","volume":"35","author":"Ruchala","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2016.11.010_bib0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jnutbio.2008.07.014","article-title":"The ironregulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes","volume":"20","author":"Ge","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0235","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1073\/pnas.1422373112","article-title":"Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function","volume":"112","author":"Lakhal-Littleton","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.11.010_bib0240","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","author":"Melenovsky","year":"2016","journal-title":"Eur. J. Heart Failure"},{"key":"10.1016\/j.phrs.2016.11.010_bib0245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2016.11.010_bib0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11010-011-0808-3","article-title":"Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats","volume":"354","author":"Melenovsky","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0255","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.ijcard.2013.12.067","article-title":"Hepcidin is increased in the hypertrophied heart of Dahl salt-sensitive rats","volume":"172","author":"Naito","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0260","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2215\/CJN.01000211","article-title":"Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary Bypass","volume":"6","author":"Ho","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"January (29)","key":"10.1016\/j.phrs.2016.11.010_bib0265","article-title":"Renal handling of circulating and renal-Synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury","author":"van Swelm","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0270","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-5793(00)01920-7","article-title":"LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity","volume":"480","author":"Krause","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2016.11.010_bib0275","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0280","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.peptides.2010.08.007","article-title":"Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: effect of copper and acidic pH","volume":"31","author":"Maisetta","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0285","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.peptides.2010.08.007","article-title":"Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: effect of copper and acidic pH","volume":"31","author":"Maisetta","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0290","first-page":"435","article-title":"Inhibitory effect of the human liver-derived antimicrobial peptide hepcidin 20 on biofilms of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains of Staphylococcus epidermidis","volume":"3020","author":"Brancatisano","year":"2016","journal-title":"Biofouling"},{"key":"10.1016\/j.phrs.2016.11.010_bib0295","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.peptides.2011.10.012","article-title":"Fungicidal activity of the human peptide hepcidin 20 alone or in combination with other antifungals against Candida glabrata isolates","volume":"32","author":"Tavanti","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0300","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1128\/AAC.00904-13","article-title":"Antifungal activity of the non cytotoxic human peptide hepcidin 20 against fluconazole resistant Candida glabrata in human vaginal fluid","volume":"57","author":"Del Gaudio","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2016.11.010_bib0305","doi-asserted-by":"crossref","first-page":"L799","DOI":"10.1152\/ajplung.2000.279.5.L799","article-title":"Synergistic and additive killing by antimicrobial factors found in human airway surface liquid","volume":"279","author":"Singh","year":"2000","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11908-010-0137-9","article-title":"Vulvovaginal candidiasis caused by non-albicans candida species: new insights","volume":"12","author":"Kennedy","year":"2010","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.phrs.2016.11.010_bib0315","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1128\/AAC.00904-13","article-title":"Antifungal activity of the non cytotoxic human peptide hepcidin 20 against fluconazole resistant Candida glabrata in human vaginal fluid","volume":"57","author":"Del Gaudio","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2016.11.010_bib0320","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1189\/jlb.0407216","article-title":"Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis","volume":"82","author":"Sow","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0325","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.peptides.2012.06.001","article-title":"Importance of the disulfide bridges in the antibacterial activity of human hepcidin","volume":"36","author":"Hocquellet","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0330","doi-asserted-by":"crossref","first-page":"22711","DOI":"10.3390\/ijms160922711","article-title":"The use of a liposomal formulation incorporating an antimicrobial peptide from tilapia as a new adjuvant to epirubicin in human squamous cell carcinoma and pluripotent testicular embryonic carcinoma cells","volume":"16","author":"Lo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2016.11.010_bib0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.peptides.2010.11.003","article-title":"Tilapia (Oreochromis mossambicus) antimicrobial peptide, hepcidin 1\u20135, shows antitumor activity in cancer cells","volume":"32","author":"Chang","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0340","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.peptides.2009.06.009","article-title":"A fish antimicrobial peptide, tilapia hepcidin TH2-3, shows potent antitumor activity against human fibrosarcoma cells","volume":"30","author":"Chen","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2016.11.010_bib0345","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.gastro.2010.06.013","article-title":"Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment","volume":"139","author":"Pietrangelo","year":"2010","journal-title":"Gastroenterology"},{"issue":"August (6)","key":"10.1016\/j.phrs.2016.11.010_bib0350","article-title":"Clinical trials update in new treatments of \u03b2-thalassemia","author":"Makis","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0355","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.13812","article-title":"Management of polycythaemia vera: a critical review of current data","volume":"172","author":"McMullin","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0360","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/13543784.2016.1182981","article-title":"Investigational therapies for renal disease-induced anemia","volume":"25","author":"Schmid","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2016.11.010_bib0365","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1157121","article-title":"The serine protease TMPRSS6 is required to sense iron deficiency","volume":"320","author":"Du","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.11.010_bib0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.130","article-title":"Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)","volume":"40","author":"Finberg","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2016.11.010_bib0375","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jcmm.12462","article-title":"Identification of TMPRSS6 cleavage sites of hemojuvelin","volume":"19","author":"Rausa","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2016.11.010_bib0380","doi-asserted-by":"crossref","first-page":"e1608","DOI":"10.1542\/peds.2010-1123","article-title":"Iron-deficiency anemia in Castleman disease: implication of the interleukin 6\/hepcidin pathway","volume":"126","author":"Arlet","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.phrs.2016.11.010_bib0385","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1208\/s12248-010-9222-0","article-title":"Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9 m and hepcidin in cynomolgus monkeys","volume":"12","author":"Xiao","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2016.11.010_bib0390","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrd4503","article-title":"A holistic approach to targeting disease with polymeric nanoparticles","volume":"14","author":"Cheng","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.11.010_bib0395","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0400","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0405","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2012-07-440743","article-title":"Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis","volume":"120","author":"Ramos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0410","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bmcl.2014.12.094","article-title":"Thiol-derivatized mini-hepcidins retain biological activity","volume":"25","author":"Fung","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2016.11.010_bib0415","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.bmcl.2015.03.012","article-title":"Small cyclic agonists of iron regulatory hormone hepcidin","volume":"25","author":"Chua","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2016.11.010_bib0420","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2010.07.044","article-title":"BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice","volume":"139","author":"Corradini","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.11.010_bib0425","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/cvr\/cvv221","article-title":"Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells","volume":"108","author":"Yung","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2016.11.010_bib0430","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of \u03b2-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0435","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0440","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0445","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ajh.23934","article-title":"Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of \u03b2-thalassemia intermedia","volume":"90","author":"Schmidt","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0450","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0455","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/cbic.201500651","article-title":"En route to new therapeutic options for iron overload diseases: matriptase-2 as a target for kunitz-type inhibitors","volume":"17","author":"Beckmann","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.phrs.2016.11.010_bib0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bcmd.2014.06.002","article-title":"A chemical screen identifies small molecules that regulate hepcidin expression","volume":"53","author":"Gaun","year":"2014","journal-title":"Blood Cells. Mol. Dis."},{"key":"10.1016\/j.phrs.2016.11.010_bib0465","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/hep.26490","article-title":"The small molecule, genistein, increases hepcidin expression in human hepatocytes","volume":"58","author":"Zhen","year":"2013","journal-title":"Hepatology"},{"issue":"March (6)","key":"10.1016\/j.phrs.2016.11.010_bib0470","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2013-07-515957","article-title":"Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras\/RAF and nutrient-dependent mTOR signaling","volume":"123","author":"Mleczko-Sanecka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0475","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI83831","article-title":"Progesterone receptor membrane component-1 regulates hepcidin biosynthesis","volume":"126","author":"Li","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0480","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1210\/en.2011-2045","article-title":"17\u03b2-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site","volume":"153","author":"Yang","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2016.11.010_bib0485","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.chembiol.2008.05.011","article-title":"The small-molecule iron transport inhibitor ferristatin\/NSC306711 promotes degradation of the transferrin receptor","volume":"15","author":"Horonchik","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0490","doi-asserted-by":"crossref","first-page":"e70199","DOI":"10.1371\/journal.pone.0070199","article-title":"Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo","volume":"8","author":"Byrne","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.11.010_bib0495","doi-asserted-by":"crossref","first-page":"G1019","DOI":"10.1152\/ajpgi.00324.2014","article-title":"The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro","volume":"308","author":"Alkhateeb","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0500","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3892\/ijmm.2016.2545","article-title":"Icariin regulates systemic iron metabolism by increasing hepatic hepcidin expression through Stat3 and Smad1\/5\/8 signaling","volume":"37","author":"Zhang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2016.11.010_bib0505","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood-2010-09-309708","article-title":"Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation","volume":"117","author":"Perlstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0510","first-page":"19","article-title":"The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes","volume":"1","author":"Zughaier","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0515","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2013040355","article-title":"Suppression of iron-regulatory hepcidin by vitamin D","volume":"25","author":"Bacchetta","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0520","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2013-07-515221","article-title":"Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo","volume":"123","author":"Poli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0525","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1042\/BST0340458","article-title":"Heparin\/heparan sulphate binding in the TGF-beta cytokine superfamily","volume":"34","author":"Rider","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.phrs.2016.11.010_bib0530","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bcp.2014.09.007","article-title":"Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo","volume":"92","author":"Poli","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0540","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fphar.2015.00316","article-title":"High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin","volume":"6","author":"Asperti","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0545","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0550","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","article-title":"BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism","volume":"41","author":"Jr Andriopoulos","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2016.11.010_bib0555","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.010_bib0560","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","article-title":"Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0565","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1208\/s12248-015-9770-4","article-title":"Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation","volume":"17","author":"B\u00f6ser","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2016.11.010_bib0570","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","article-title":"Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels","volume":"101","author":"Kovac","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2016.11.010_bib0575","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.688.688","article-title":"Targeting the hepcidin pathway with RNAi therapeutics for the treatment of anemia","volume":"118","author":"Akinc","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0580","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0585","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0590","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2014.111484","article-title":"Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation","volume":"100","author":"Mayeur","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2016.11.010_bib0595","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/ndt\/gfs584","article-title":"A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats","volume":"28","author":"Sun","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2016.11.010_bib0600","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/ATVBAHA.111.240101","article-title":"Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis, Finn AV","volume":"32","author":"Saeed","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0605","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/1538-7445.AM2015-3647","article-title":"Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors","author":"Peterson","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.11.010_bib0610","unstructured":"http:\/\/www.toleropharma.com\/TP-0184.html (accesses 08 21 16)"},{"key":"10.1016\/j.phrs.2016.11.010_bib0615","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2006-07-033969","article-title":"STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation","volume":"109","author":"Verga Falzacappa","year":"2007","journal-title":"Blood"},{"issue":"Suppl (2)","key":"10.1016\/j.phrs.2016.11.010_bib0620","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2016.11.010_bib0625","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2016.11.010_bib0630","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0635","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1365-2141.2000.02127.x","article-title":"JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells","volume":"109","author":"De Vos","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0640","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1535-7163.261.3.3","article-title":"Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2016.11.010_bib0645","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00109-009-0588-3","article-title":"Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form","volume":"88","author":"Fatih","year":"2010","journal-title":"J. Mol. Med. (Berl)."},{"key":"10.1016\/j.phrs.2016.11.010_bib0650","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.3748\/wjg.v17.i45.5032","article-title":"AG490: an inhibitor of hepcidin expression in vivo","volume":"17","author":"Zhang","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0655","first-page":"263","article-title":"The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain","volume":"1","author":"McMurray","year":"2012","journal-title":"JAKSTAT"},{"key":"10.1016\/j.phrs.2016.11.010_bib0660","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.3748\/wjg.v17.i45.5032","article-title":"AG490: an inhibitor of hepcidin expression in vivo","volume":"17","author":"Zhang","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0665","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0670","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2008-05-155952","article-title":"Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator","volume":"113","author":"Jiao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0675","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543776.2014.877443","article-title":"Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature","volume":"24","author":"Lavecchia","year":"2014","journal-title":"Exp. Opi. Ther. Pat."},{"key":"10.1016\/j.phrs.2016.11.010_bib0680","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"J. Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.11.010_bib0685","first-page":"94","article-title":"Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo","volume":"6","author":"Kandala","year":"2012","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.phrs.2016.11.010_bib0690","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/carcin\/bgm017","article-title":"Gene expression analysis during tumor enhancement by the dietary phytochemical, 3,3'-diindolylmethane, in rainbow trout","volume":"28","author":"Tilton","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phrs.2016.11.010_bib0695","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/ars.2015.6315","article-title":"Hydrogen sulfide attenuates inflammatory hepcidin by reducing IL-6 secretion and promoting SIRT1-mediated STAT3 deacetylation","volume":"24","author":"Xin","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2016.11.010_bib0700","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3945\/jn.113.174201","article-title":"Screening identifies the Chinese medicinal plant Caulis Spatholobi as an effective HAMP expression inhibitor","volume":"143","author":"Guan","year":"2013","journal-title":"J. Nutr."},{"key":"10.1016\/j.phrs.2016.11.010_bib0705","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","article-title":"Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia","volume":"126","author":"Kautz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0710","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-12-396962-0.00007-0","article-title":"Anticalins small engineered binding proteins based on the lipocalin scaffold","volume":"503","author":"Gebauer","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.phrs.2016.11.010_bib0715","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1373\/clinchem.2014.221671","article-title":"Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin","volume":"60","author":"Grebenchtchikov","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.11.010_bib0720","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.687.687","article-title":"Discovery and preclinical characterization of a novel hepcidin antagonist with tunable PK\/PD properties for the treatment: of anemia in different patient populations","volume":"118","author":"Hohlbaum","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0725","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drudis.2014.09.004","article-title":"Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(\u00ae) therapeutics","volume":"20","author":"Vater","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2016.11.010_bib0730","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0735","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2342.2342","article-title":"Single and repeated dose first-in-human study with the anti-hepcidin spiegelmer nox-H94","volume":"120","author":"Riecke","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0740","doi-asserted-by":"crossref","DOI":"10.1186\/cc12290","article-title":"Randomized double-blind placebo-controlled PK\/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia","volume":"17","author":"Van Eijk","year":"2013","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2016.11.010_bib0745","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-3847","article-title":"The anti-hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study","volume":"74","author":"Georgiev","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.11.010_bib0750","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0755","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2013-06-505792","article-title":"A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates","volume":"122","author":"Cooke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.010_bib0760","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/mol.112.083428","article-title":"High-throughput screening of small molecules identifies hepcidin antagonists","volume":"83","author":"Fung","year":"2013","journal-title":"Mol. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816308763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816308763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:26:21Z","timestamp":1749738381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816308763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":152,"alternative-id":["S1043661816308763"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of hepcidin \u2212 the master regulator of iron metabolism","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}